Abstracts tagged "diagnosis and interferons"

Abstract Number: 664 • 2019 ACR/ARP Annual Meeting
Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus
Wietske Lambers¹, Karina de Leeuw ², Femke Homan ¹, Berber Doornbos-van der Meer ¹, Hendrika Bootsma ³, Johanna Westra ² and Gilles Diercks ¹, ¹UMCG, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous auto-inflammatory skin disease, that is driven to a great extent by interferon (IFN) type I1, and is…
Abstract Number: 3200 • 2015 ACR/ARHP Annual Meeting
Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model
Astrid Rasmussen¹, Christopher J Lessard², Indra Adrianto¹, Graham B. Wiley¹, Donald U Stone^3,4, C. Erick Kaufman⁵, Lida Radfar⁶, David M. Lewis⁷, Stephen K Young⁸, Michael H. Weisman⁹, Daniel J Wallace¹⁰, Swamy Venuturupalli¹¹, Barbara M. Segal¹², John A. Ice¹, Juan-Manuel Anaya¹³, Michael D. Rohrer¹⁴, Raj Gopalakrishnan¹⁵, Glen D Houston¹⁶, James Chodosh¹⁷, Pamela J Hughes¹⁸, Nelson L. Rhodus¹⁹, Jennifer A. Kelly²⁰, Kiely Grundahl²¹, Kimberly Hefner²², R. Hal Scofield^1,23,24 and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁴Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, ⁵College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁷College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹³Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁴Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁵Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ¹⁶Heartland Pathology, Oklahoma City, OK, ¹⁷Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹⁸Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, ¹⁹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁰Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ²²Hefner Eye Care and Optical Center, Oklahoma City, OK, ²³Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Autoimmune diseases are often preceded by subclinical serologic and functional abnormalities that predate diagnosis by several years. The insidious and progressive nature of these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].